NCT07125664View on ClinicalTrials.gov

Intravenous Alpha-1 Antitrypsin for Hospitalized Patients With COPD Exacerbations (AECOPD Study)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 7, 2027

Study Completion Date

December 1, 2027

Conditions
Acute Exacerbation Chronic Obstructive Pulmonary Disease
Interventions
BIOLOGICAL

alpha1-proteinase inhibitor, produced from the plasma of human donors (Prolastin 1000 mg, powder and solvent for solution for infusion)

IV Prolastin administered once at 120 mg per kilogram of body weight

DRUG

Placebo

\+ IV administration of 0.9% sodium chloride

Trial Locations (1)

27100

Fondazione IRCCS Policlinico San Matteo, Pavia

All Listed Sponsors
lead

Fondazione IRCCS Policlinico San Matteo di Pavia

OTHER